Last updated: March 23, 2026
What is the drug identified by NDC 72603-0337?
NDC 72603-0337 corresponds to Xyrem (sodium oxybate), used primarily for treating narcolepsy with cataplexy. The drug is marketed by Jazz Pharmaceuticals.
Market Overview
Market size and usage:
Xyrem has faced steady demand since its approval in 2002. Its primary use is narcolepsy with cataplexy, a rare sleep disorder affecting approximately 200,000 Americans. The drug’s high efficacy in reducing symptom severity ensures sustained demand among prescribers.
Competitive landscape:
Xyrem’s main competitor is Wakix (pitolisant) by Harmony Biosciences, approved in 2019 for narcolepsy. Other therapies include modafinil and methylphenidate, but these target wakefulness rather than cataplexy and sleep paralysis directly.
Regulatory status:
Issued with Schedule III classification under the Controlled Substances Act due to its gamma-hydroxybutyrate (GHB) content, the drug’s regulatory environment influences supply chain security and pricing.
Market Drivers:
- Increasing awareness of narcolepsy diagnosis.
- Expanded insurance coverage.
- Adoption of the drug in off-label indications, such as alcohol addiction and PTSD.
Challenges:
- Stringent regulation impacts supply and pharmacy stocking.
- Side effect profile limits patient candidacy.
- Price sensitivity in healthcare systems and payers.
Pricing History and Trends
| Year |
Average Wholesale Price (AWP) per gram |
Estimated Monthly Cost (for typical dose) |
| 2018 |
$250 |
$4,300 |
| 2020 |
$260 |
$4,500 |
| 2022 |
$270 |
$4,700 |
| 2023 |
$275 |
$4,800 |
Note: Prices are approximate and vary by distributor, insurance, and geographic region.
The price per gram has increased approximately 10% over the past five years. Manufacturers have maintained high list prices, justified by the drug’s complexity, regulatory costs, and limited competition.
Price Projection for Next Five Years
Assumption Basis:
- No significant patent challenges or generic competition before 2025.
- Continued demand in narcolepsy treatment.
- Incremental annual price increases within 3–5%.
| Year |
Estimated Price per Gram |
Monthly Cost Estimate |
Comments |
| 2024 |
$280 |
$4,900 |
Slight increase due to inflation and regulatory costs |
| 2025 |
$290 |
$5,050 |
Expected new formulary placements |
| 2026 |
$300 |
$5,200 |
Potential market stabilization |
| 2027 |
$310 |
$5,350 |
Slight premium for supply chain tightness |
| 2028 |
$320 |
$5,500 |
Anticipated slow growth, potential price negotiations |
Prices are projected, assuming no major regulatory, patent, or clinical paradigm shifts.
Regulatory and Patent Outlook
Patent Status:
Jazz Pharmaceuticals previously held patents expiring in the mid-2020s. Efforts for patent extensions and new formulations aim to delay generic entry.
Regulatory Environment:
Stricter safety monitoring could drive up compliance costs, indirectly impacting pricing. No current plans for regulatory changes are anticipated to directly affect the drug’s pricing.
Market Entry of Generics
Depending on patent litigation outcomes, generic versions could enter in late 2024 or early 2025. Generic entry would potentially suppress prices by 60–70%, aligning the drug’s market price closer to $1,100–$1,300 per 30-day supply.
Strategic Implications
- Pricing remains elevated due to the drug’s limited competition and high clinical value.
- Market stability is contingent on patent protections and regulatory costs.
- Generic competition will drive downward pressure in the near term, risking a 50% reduction in retail prices.
Key Takeaways
- The drug faces a mature but stable market with steady demand.
- Prices have increased modestly, reflecting inflation and regulatory costs.
- Significant generic competition is imminent, likely causing substantial price reductions.
- Prices are projected to rise slightly until patent expiration, then decrease sharply with generics entering the market.
- The outlook emphasizes the importance of patent strategy and regulatory navigation for maintaining pricing power.
FAQs
1. What factors influence the price of NDC 72603-0337?
Manufacturing costs, regulatory compliance, patent protections, market demand, and competitive pressures directly affect price levels.
2. When is the generic version expected to enter the market?
Late 2024 to early 2025, contingent upon patent litigation outcomes and regulatory approvals.
3. How does competition impact the drug’s future pricing?
Generic entry typically reduces prices by 50–70%, shrinking margins and impacting revenue projections.
4. Are there regulatory risks that could alter price trends?
Enhanced safety regulations can increase compliance costs, indirectly affecting pricing; no major regulatory reforms are currently anticipated.
5. What is the potential patient access impact from price changes?
Price reductions from generics may improve patient access, but high individual costs may persist without insurance coverage.
